Navigation Links
Alexza Pharmaceuticals to Present at the 18th Annual NewsMakers in the Biotech Industry Conference
Date:10/11/2011

nd initially submitted the ADASUVE NDA in December 2009.  In October 2010, the Company received a Complete Response Letter from the FDA regarding the application.  The Company completed an end-of-review meeting with the FDA in December 2010 and a Risk Evaluation and Mitigation Strategy (REMS) guidance meeting with the FDA in April 2011.  The ADASUVE NDA was resubmitted on August 4, 2011, and has a Prescription Drug User Fee Act (PDUFA) goal date of February 4, 2012.  The FDA has indicated that it will likely present the ADASUVE application to an Advisory Committee during the review period.  

Alexza also plans to file the ADASUVE Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in the fourth quarter of 2011.  In October 2011, the Company established a commercial partnership for ADASUVE with Grupo Ferrer International, S.A.  Grupo Ferrer is a leading pharmaceutical company in Europe with extensive operations in the Americas, and is Alexza's partner in the registration, distribution and promotion of ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.  

For more information about Alexza, the Staccato system technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the adequacy of the Company's capital to support the Company's operatio
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... 21, 2014  Zacks.com announces the list of stocks featured ... analysts discuss the latest news and events impacting stocks and ... Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH - Free Report ), ... Lilly and Company (NYSE: LLY - Free Report ), ... Inc. (Nasdaq: ITMN - Free Report ). ...
(Date:7/21/2014)... Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... treatments for cancer and its associated pain, today announced ... development of a small molecule inhibitor targeting the important ... protein has also been recognized as an important determinant ... as a dominant factor in most human cancers and ...
(Date:7/21/2014)...  A new Journal of the American Medical ... to appear in the August 13 print edition addresses ... C Virus (HCV) treatments such as Sovaldi (sofosbuvir) and ... (NYSE: CVS ) Chief Medical Officer Troyen ... Shrank , M.D., suggest that the discussion to this ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 2The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 3The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 4The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 5The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 6The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 7Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 2Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 3Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 4CVS Caremark JAMA Commentary: New Hepatitis C Treatments Highlight Need to Control Costs of High-Priced Specialty Medications 2CVS Caremark JAMA Commentary: New Hepatitis C Treatments Highlight Need to Control Costs of High-Priced Specialty Medications 3
... INDIANAPOLIS and ROLLING MEADOWS, Ill., April 4, 2012 ... the Diabetes Scholars Foundation (Foundation) scholarship fund. The contribution ... with type 1 diabetes to live their lives to ... fund college scholarships for students with type 1 diabetes ...
... 2012   Sunpeaks Ventures, Inc. (OTCBB: SNPK) ... its wholly owned subsidiary Healthcare Distribution Specialists, LLC ... has entered into an Agreement with Albeck Financial ... Albeck will provide outsourced Chief Financial Officer services, ...
Cached Medicine Technology:Lilly Diabetes supports Diabetes Scholars Foundation with $100,000 donation in 2012 2Lilly Diabetes supports Diabetes Scholars Foundation with $100,000 donation in 2012 3Sunpeaks Ventures Announces Agreement with Albeck Financial Services 2
(Date:7/22/2014)... 2014 Recently, MyDressCity.com has excitedly launched a ... the moment, all people can get a discount, up to ... styles in the new range; all the new items are ... the prettiest Quinceanera gowns for worldwide clients. Our dress specialists ... the CEO of MyDressCity.com, “Our Quinceanera dresses are selling well ...
(Date:7/22/2014)... MA (PRWEB) July 22, 2014 ... Research Group announces publication of a new ... Risk & Compliance: 2014 ProductMatrixTM Vendor Evaluations ”. ... end-user organizations with best practice benchmarking, vendor evaluations ... governance, risk, and compliance software solutions, what tangible ...
(Date:7/22/2014)... July 22, 2014 Visitors to the ... Expo (Chicago, July 29-31) will have the opportunity to ... and preanalytical errors. Radiometer will host two sessions of ... Developing an Individualized Quality Control Plan (IQCP) for Blood ... 2:00—2:30 PM, Sy Albakri, PhD, Clinical and Scientific Affairs ...
(Date:7/22/2014)... Woodland Hills, CA (PRWEB) July 22, 2014 ... but your dental health as well, according to two of ... Saj Jivraj and Dr. Mamaly Reshad of the Anacapa Dental ... negative effects of not taking care of one’s teeth. They ... functional smiles. , “If you are not seeing a dentist ...
(Date:7/22/2014)... Recently, 2014quinceaneradresses.com, a popular online shop of women’s special ... blue and white Quinceanera dresses . Moreover, the company ... hoping to show appreciation to the international clients. All ... price, up to 60% off. , Its major ... As one of the leaders in the fashion industry, ...
Breaking Medicine News(10 mins):Health News:Beautiful Dama Dresses Now Released By Popular Online Supplier MyDressCity.com 2Health News:Hypatia Research Group Publishes “Enterprise Governance, Risk & Compliance: Best Practices, Maturity Models and 2014 ProductMatrix Vendor Evaluations” 2Health News:Hypatia Research Group Publishes “Enterprise Governance, Risk & Compliance: Best Practices, Maturity Models and 2014 ProductMatrix Vendor Evaluations” 3Health News:Hypatia Research Group Publishes “Enterprise Governance, Risk & Compliance: Best Practices, Maturity Models and 2014 ProductMatrix Vendor Evaluations” 4Health News:Radiometer Features Booth Presentations On IQCP and Blood Gas Preanalytics at the 2014 AACC Clinical Lab Expo 2Health News:Ventura’s Best Cosmetic Dentists Offer 4 Tips for Improving Dental Health Through Nutrition 2Health News:Ventura’s Best Cosmetic Dentists Offer 4 Tips for Improving Dental Health Through Nutrition 3Health News:Ventura’s Best Cosmetic Dentists Offer 4 Tips for Improving Dental Health Through Nutrition 4Health News:Ventura’s Best Cosmetic Dentists Offer 4 Tips for Improving Dental Health Through Nutrition 5Health News:Blue and White Quinceanera Dresses at Low Prices Offered by 2014quinceaneradresses.com 2
... Oct. 24 (HealthDay News) -- Changing to daylight savings time ... appears that their internal body clocks never really adjusts to ... time can cause a significant seasonal disruption that might have ... the Oct. 24 online edition of Current Biology . ...
... way of ... daily dose of glucosamine, SAN FRANCISCO, Oct. 24 Joint ... help,people keep their joints hydrated and moving smoothly.* The company,launched today ... products: -- Original Joint Juice: ready-to-drink juice-based dietary supplement ...
... China, Oct. 24 /Xinhua-PRNewswire-FirstCall/,-- Genesis Technology Group ... known as,Genesis Pharmaceutical Enterprises, Inc.) ("GTEC" or ... People,s Republic of China ("PRC"),today announced that ... and execute its,investor relations campaign. Genesis, ...
... man to reach his goal of attending,college, SHALERSVILLE, Ohio, ... can change in a moment. His own changed,dramatically when a ... the waist down. Now, with help from The SCOOTER Store,his ... -- with its gift of,a power wheelchair. He will have ...
... of Pennsylvania Center for Education and Research on Therapeutics ... four years to continue and expand its work on ... Penn CERT is a collaboration among Penns Center for ... the Hospital of the University of Pennsylvania, as well ...
... of Pocket Expenses ... for Medical Foods, ... announced today that it has,provided a $250,000 grant to the National ... for patients with,phenylketonuria (PKU), a rare genetic metabolic disorder. Funds from ...
Cached Medicine News:Health News:Body's Clock Never Adjusts to Daylight Savings Time 2Health News:Body's Clock Never Adjusts to Daylight Savings Time 3Health News:Joint Juice Helps America Hydrate Its Joints* With New High Value Coupon Offer 2Health News:Joint Juice Helps America Hydrate Its Joints* With New High Value Coupon Offer 3Health News:Genesis Technology Group Retains CCG Elite 2Health News:Genesis Technology Group Retains CCG Elite 3Health News:The SCOOTER Store Donates Power Wheelchair to Paraplegic, a Victim of Accidental Shooting 2Health News:University of Pennsylvania receives $4M for Center for Education and Research on Therapeutics 2Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 2Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 3Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 4Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 5
... LV lead is designed to ensure ... procedure times, delivering a complete package ... QuickSite LV lead is a highly ... including such features as S-shaped fixation, ...
... Tibial Nail System is designed ... of existing implants and expand ... nails. It is available in ... and lengths and can be ...
Arthroscopic instrument system for instability and SLAP fixation....
Arthroscopic instrument system for instability and SLAP fixation....
Medicine Products: